LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Edwards Lifesciences Corp

Closed

SectorHealthcare

78.27 0.1

Overview

Share price change

24h

Current

Min

78.13

Max

78.36

Key metrics

By Trading Economics

Income

-27M

332M

Sales

120M

1.5B

P/E

Sector Avg

32.703

34.427

EPS

0.64

Profit margin

21.636

Employees

15,800

EBITDA

-34M

400M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+13.72% upside

Dividends

By Dow Jones

Next Earnings

23 Oct 2025

Market Stats

By TradingEconomics

Market Cap

978M

46B

Previous open

78.17

Previous close

78.27

News Sentiment

By Acuity

23%

77%

45 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Edwards Lifesciences Corp Chart

Past performance is not a reliable indicator of future results.

Related News

6 Aug 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

FTC Files Lawsuit to Block Edwards Lifesciences' Purchase of JenaValve Technology

25 Oct 2024, 09:10 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

25 Oct 2024, 08:35 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

3 Sept 2024, 20:38 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences: After Recent Accelerated Repurchase Agreement and August Buybacks Via 10b5-1 Agreement and Open Market Repurchases, Company Has $1.4B in Remaining Authorization

3 Sept 2024, 20:37 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Completes Sale of Critical Care Group to Becton Dickinson for $4.2B

3 Sept 2024, 20:36 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Authorizes $1.5B of Additional Share Repurchases

Peer Comparison

Price change

Edwards Lifesciences Corp Forecast

Price Target

By TipRanks

13.72% upside

12 Months Forecast

Average 89 USD  13.72%

High 101 USD

Low 80 USD

Based on 26 Wall Street analysts offering 12 month price targets forEdwards Lifesciences Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

26 ratings

16

Buy

10

Hold

0

Sell

Technical Score

By Trading Central

74.52 / 75.54Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

45 / 374 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.